Get the Daily Brief
Latest Biotech News
Polymyxin B Mechanism Unveiled: Antibiotic Targets Active Bacteria Armor
In a revealing study published in Nature Microbiology, researchers from University College London and Imperial College London elucidated how polymyxin B, a last-resort antibiotic, disrupts...
Disrupting Glioblastoma: Biodegradable Scaffold Delivers TLR7/8 Agonist
Researchers have developed a novel biodegradable scaffold that locally delivers toll-like receptor 7/8 (TLR7/8) agonists, significantly improving immunotherapy efficacy against glioblastoma in...
RSV Vaccines Confirmed Safe and Effective in Large-Scale Reviews
Comprehensive analyses including a Cochrane systematic review encompassing over 100,000 participants have affirmed the safety and robust efficacy of respiratory syncytial virus (RSV) vaccines in...
uniQure's Gene Therapy Slows Huntington’s Disease Progression by 75%
uniQure reported groundbreaking 36-month clinical trial data demonstrating that its gene therapy candidate AMT-130 achieved a remarkable 75% slowing of Huntington’s disease progression at high...
FDA Reconsiders Surrogate Endpoints in Drug Approvals, CDER Director States
George Tidmarsh, director of the FDA’s Center for Drug Evaluation and Research (CDER), announced the agency’s intent to closely reevaluate the use of surrogate endpoints employed to accelerate...
AI-Powered Molecular Search Expands Chemical Space Trillions-Fold
Cadence Molecular Sciences has launched ROCS X, an AI-enabled virtual screening platform capable of conducting three-dimensional searches across trillions of drug-like molecules. Developed in...
Novel mRNA Vaccine Suppresses Neovascularization in Age-Related Macular Degeneration
Researchers at the Institute of Science Tokyo developed an mRNA vaccine that, when administered intramuscularly, effectively suppresses pathological retinal neovascularization in mouse models of...
Breakthrough in Simultaneous In Vitro Synthesis of All 21 tRNA Types
Researchers from the University of Tokyo and RIKEN Center for Biosystems Dynamics Research have pioneered a method enabling the simultaneous synthesis of all 21 transfer RNA species essential for...
Phase III Trial Shows Intensity-Modulated Radiotherapy and Proton Therapy Equivalent for Head and Neck Cancer
The TORPEdO Phase III clinical trial demonstrated that intensity-modulated radiation therapy (IMRT) and proton beam therapy (PBT) provide comparable patient-reported outcomes in the treatment of...
Genmab’s $8 Billion Merus Acquisition Sharpens Oncology Pipeline
Genmab is set to acquire Dutch biotech Merus for approximately $8 billion in cash, gaining full rights to a promising bispecific antibody targeting head and neck cancer. Merus’ petosemtamab drug...
GSK CEO Emma Walmsley Steps Down After Transformative Nine-Year Tenure
Emma Walmsley, the first female CEO of a major pharmaceutical company, will step down as GSK’s leader at the end of 2025. Her successor, Luke Miels, currently GSK’s chief commercial officer, will...
FDA Approves Guardant Health Blood Test as Companion Diagnostic for Breast Cancer
The FDA granted approval to Guardant Health’s Guardant360 assay as a companion diagnostic to support Eli Lilly’s Inluriyo breast cancer drug. This marks the sixth companion diagnostic cleared for...
Volition and Hologic Team to Co-Market Epigenetic Profiling Service
Volition and Hologic announced a partnership to co-market Volition’s Nu.Q Discover epigenetic profiling service via Hologic’s Diagenode business. The service utilizes nucleosome quantification...
IO Biotech Halves Workforce Following FDA Setback on Cancer Vaccine Approval
IO Biotech has reduced its workforce by 50% after the FDA recommended against submitting an approval application based on failed Phase 3 melanoma trial data for their therapeutic vaccine Cylembio....
Sanofi Doubles Down on Biotech Investing with $625 Million Venture Fund Expansion
Sanofi announced a $625 million capital infusion into its corporate venture unit, Sanofi Ventures, raising total assets above $1.4 billion. The expanded evergreen fund aims to back early to...
UniQure’s Gene Therapy Shows 75% Slowing of Huntington’s Disease Progression
UniQure’s AMT-130 gene therapy delivered remarkable results, showing a statistically significant 75% slowing in Huntington's disease progression over 36 months in high-dose patients, according to...
New mRNA Vaccine Shows Promise Against Food and Seasonal Allergies
Researchers at the University of Pennsylvania and Cincinnati Children’s have developed a pioneering mRNA vaccine aiming to prevent severe allergic reactions to common foods and seasonal allergens....
New HPV Test Delivers Affordable, One-Hour Cervical Cancer Screening in Africa
A collaborative research initiative led by Rice University, Mozambique institutions, and MD Anderson Cancer Center has developed a revolutionary HPV test offering rapid results in under one hour....
Breakthrough Study Reveals Cancer Cell Stress Response as Therapeutic Target
New research uncovers the unfolded protein response (UPR) as a key adaptive mechanism enabling cancer cells to survive persistent cellular stress. Detailed in recent findings, this stress pathway...
uniQure’s Huntington’s Gene Therapy Slows Disease Progression Dramatically
UniQure has reported highly promising 36-month clinical data for AMT-130, its gene therapy candidate for Huntington’s disease (HD). The Phase I/II study demonstrated a statistically significant...